(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 14.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Mimedx Group's revenue in 2026 is $393,442,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $59,845,120,409, with the lowest MDXG revenue forecast at $51,147,080,611, and the highest MDXG revenue forecast at $72,296,068,916. On average, 6 Wall Street analysts forecast MDXG's revenue for 2027 to be $68,972,656,468, with the lowest MDXG revenue forecast at $58,781,746,907, and the highest MDXG revenue forecast at $81,813,113,653.
In 2028, MDXG is forecast to generate $90,200,138,917 in revenue, with the lowest revenue forecast at $86,663,459,360 and the highest revenue forecast at $92,854,129,607.